Tristel has appointed Anna Wasyl as its new chief financial officer (CFO), with effect from 1 September 2025.

Wasyl will replace Liz Dixon, who stepped down from the role on 30 June 2025, after working at the infection prevention products manufacturer since 2007.

She joins the firm from CMR Surgical, where she served as chief commercial partnerships and operations officer, having previously held the role of group CFO.

Tristel said that Wasyl brings a "rare blend" of operational, strategic and financial expertise, with over 20 years of experience across publicly listed and venture-backed companies.

Through her career, she has led cross-functional teams, has overseen business operations with revenues up to $1bn and has raised over $200m in capital.

Wasyl said: "I am honoured to join Tristel as its new CFO. Tristel has established a well-earned reputation for innovation and leadership in infection prevention, and I look forward to being CFO for this exceptional business. I am eager to build on the strong financial and strategic foundation established by Dixon, and to working closely with the board, executive leadership, and global teams to drive long-term, sustainable growth.

"My priorities will include capitalising on global market opportunities, enhancing operational efficiency, and strengthening our presence in key geographies. Together, we will continue to focus on delivering growth and exceptional value to our customers and stakeholders."

Chief executive officer at Tristel, Matt Sassone, added: "Anna's appointment comes at an exciting and important time for Tristel. Her broad international background, commercial mindset, and hands-on approach to both strategy and execution are exactly what we need as we enter our next phase of growth.

"I have been impressed by her achievements in both large corporates and scale-up environments and am confident she will make a significant contribution to our board and to the business."

---